Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat + dapagliflozin vs dapagliflozin in CKD with hypertension (BaxDuo-Arctic)
jRCT2031240043Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in chronic kidney disease (CKD) and hypertension (HTN) comparing Baxdrostat + dapagliflozin with Placebo + dapagliflozin (2 arms). Primary endpoint: Primary: Change in eGFR over time. Started May 2024; status: active, not recruiting.
02
Drugs
baxdrostatdapagliflozin
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on jRCT2031240043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240043.